Illumina Settles Shareholder Suit Over Grail Deal
Healthcare companies weighing large acquisitions should treat cross-border antitrust review as a risk that can unwind a deal after closing.
Updated on Nov. 3, 2026 in Healthcare

Delaware Chancery Court approved a settlement between Carl Icahn's investment companies and Illumina's former corporate leaders, ending Delaware litigation over the failed $8 billion acquisition of cancer detection firm Grail. Healthcare investors and governance counsel should note the case closes after the court had earlier thrown out a consolidated shareholder case raising parallel claims.
Why it matters
The settlement resolves shareholder claims that Illumina's then-CEO and directors closed the Grail transaction despite active regulatory scrutiny. Because the deal was ultimately rejected by a US judge and European antitrust authorities and forced to unwind, the case shows how much regulatory risk can cost a healthcare company even after a large acquisition is completed.
The failed Illumina-Grail acquisition was valued at $8 billion, and the settlement ends Delaware litigation tied to that deal. The source does not report the settlement's dollar amount or the number of shareholders who were party to the consolidated case.
The players
Illumina
A genomic sequencing company whose instruments and tools are widely used across clinical and research laboratories.
Grail
A cancer detection firm developing blood-based screening tests, whose $8 billion acquisition by Illumina was ultimately unwound.
Carl Icahn
An activist investor whose investment companies secured the settlement with Illumina's former corporate leaders.
The details
Illumina closed its Grail transaction while regulatory reviews were still active on two continents. A US judge rejected the merger, and European antitrust authorities also rejected it, forcing Illumina to unwind the deal. Shareholder suits then blamed the company's then-CEO and directors for closing the transaction despite that scrutiny, and the Delaware litigation that followed has now been settled.
Timeline
Late October 2026: a Delaware Chancery Court judge threw out a consolidated shareholder case raising parallel claims.
Monday, week of November 3, 2026: the Delaware Chancery Court approved the settlement between Carl Icahn's investment companies and Illumina's former corporate leaders.
Market Landscape
The Illumina-Grail deal was rejected by both a US judge and European antitrust authorities, showing that cross-border regulatory review can block healthcare acquisitions after they close. This settlement closes the shareholder fallout from that precedent for the company's former leadership.
Healthcare operators involved in mergers should treat regulatory review in every relevant jurisdiction as a live closing risk, not a formality. Boards and counsel should document how they weigh pending antitrust scrutiny before completing large transactions.
The takeaway
Large healthcare acquisitions can be unwound after closing when regulators in multiple countries reject them, so compliance and governance teams should map antitrust exposure early. Companies weighing a similar deal should consult qualified antitrust and corporate counsel before closing.
Further reading
For related coverage of the sector, see Healthcare in the Delaware business section.
Source note: This article includes information reported by Bloomberglaw.




